Semaglutide is a GLP-1 receptor agonist with ~7-day half-life via albumin-binding fatty acid modification — the most extensively studied GLP-1RA, anchoring the SUSTAIN and STEP clinical programs.
Product definition
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist with ~7-day half-life via albumin-binding fatty acid modification — the most extensively studied GLP-1RA, anchoring the SUSTAIN and STEP clinical programs.
Semaglutide is a 31-amino-acid GLP-1 receptor agonist developed by Novo Nordisk. Its two critical modifications distinguish it from native GLP-1 and earlier GLP-1RA compounds: (1) Aib substitution at position 8 eliminates DPP-IV cleavage — the primary inactivation pathway for native GLP-1; (2) a C18 fatty diacid chain at position 26 (via a short linker) enables reversible albumin binding that dramatically extends half-life while maintaining GLP-1R selectivity and full agonism.
The pharmacological research profile spans multiple programs: SUSTAIN (subcutaneous semaglutide for T2D, 7 trials), STEP (subcutaneous semaglutide for obesity, 4 Phase III trials), PIONEER (oral semaglutide for T2D), and SELECT (cardiovascular outcomes in obesity without diabetes). The breadth and scale of this dataset — across ~50,000 research participants — makes semaglutide the most comprehensively characterized GLP-1 receptor agonist in the open literature, with published pharmacokinetic, pharmacodynamic, and outcomes data across glycemic, cardiovascular, renal, hepatic, and weight endpoints.
Research context
How is Semaglutide described in the research literature?
Semaglutide activates GLP-1 receptors in pancreatic beta cells (insulin secretion), hypothalamus (appetite suppression), and gastrointestinal tract (gastric emptying delay). Albumin binding via C18 fatty diacid conjugate extends half-life to ~7 days. Phase III data documents 15% body weight reduction at 68 weeks (STEP-1) and cardiovascular event reduction (SUSTAIN-6).
Compound profile
Key facts about Semaglutide
- Class
- GLP-1 receptor agonist
- Amino acids
- 31
- Molecular weight
- ~4,114 Da
- Half-life
- ~7 days (albumin-bound in vivo)
- Modification
- C18 fatty diacid conjugate + position-8 Aib substitution
- CAS
- 910463-68-2
- Clinical status
- FDA-approved (Ozempic, Wegovy, Rybelsus)
- Research category
- GLP-1 pharmacology, obesity, T2D, cardiovascular, NASH
- Storage
- Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days
Research areas
What research areas is Semaglutide associated with?
- ~7-day half-life via albumin-binding C18 fatty acid modification — weekly dosing in research protocols
- Phase III STEP-1 data: 14.9% mean body weight reduction at 68 weeks — benchmark for incretin research outcomes
- SUSTAIN-6 cardiovascular outcomes trial: MACE reduction documented in prospective design
- Studied in NASH/MASH models for hepatic lipid reduction and liver fibrosis markers
- Reference GLP-1RA for beta cell preservation, GLP-1R pharmacology, and incretin axis research
- Most clinically characterized GLP-1R agonist — SELECT outcomes trial data in non-diabetic obesity
Research audience
Who researches Semaglutide?
Semaglutide is used by researchers in metabolic disease pharmacology, GLP-1 receptor biology, obesity mechanisms, beta cell function, hepatic metabolism, and cardiovascular endocrinology. It is the reference compound for GLP-1RA class pharmacology due to the depth and scale of its published clinical and preclinical dataset.
Preclinical research overview
What does the preclinical literature say about Semaglutide?
Semaglutide was developed by Novo Nordisk through optimization of the GLP-1 analog class, drawing on the lessons of earlier GLP-1RAs (liraglutide, exenatide) to achieve weekly dosing and improved tolerability. The albumin-binding mechanism extends half-life by slowing renal filtration and proteolytic exposure while preserving the reversibility of receptor engagement.
In GLP-1 receptor biology research, semaglutide is used as a pharmacological tool because of the quality of its published receptor kinetics data. The compound shows full GLP-1R agonism with sub-nanomolar EC50, making it useful for dose-response studies examining the relationship between GLP-1R occupancy and downstream signaling (cAMP, PKA, Epac, insulin secretion).
In obesity and metabolic research, the STEP trials established that pharmacological GLP-1R activation via weekly injection can produce body weight reduction comparable in magnitude to metabolic surgery in some participants — a finding that has driven substantial academic investigation into the mechanisms of GLP-1R-mediated appetite suppression, including hypothalamic neural circuit research, gut-brain axis studies, and dopaminergic reward system interactions.
Semaglutide is also the lead comparator in trials of next-generation compounds (tirzepatide, retatrutide, cagrilintide+semaglutide), making it the pharmacological baseline for studying incretin pharmacology advancement.
Common questions
Frequently asked about Semaglutide
How does semaglutide differ from tirzepatide as a research compound?
Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. For research requiring isolated GLP-1R pharmacology without GIP receptor contribution, semaglutide is the appropriate tool. For research studying dual incretin receptor co-agonism or comparing single- vs. dual-receptor activation, tirzepatide is the reference compound. The SUSTAIN-9 trial compared both directly in T2D, providing a head-to-head pharmacological dataset.
What is semaglutide's role in NASH/liver research?
GLP-1 receptors are expressed in the liver, and semaglutide has been studied for hepatic lipid reduction, NASH histological improvement, and liver fibrosis biomarker changes in both animal models and clinical trials. The NASH program produced NASH resolution data in a Phase II trial (SUSTAIN/ESSENCE), and Phase III trials (ESSENCE) are ongoing. For researchers studying hepatic GLP-1R effects, semaglutide is the most advanced GLP-1RA in the NASH research pipeline.
What is the reconstitution and storage protocol?
Lyophilized semaglutide is stable at −20°C. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 30 days. Avoid vigorous agitation — the peptide can form aggregates under mechanical stress. The fatty acid modification makes semaglutide slightly more stable in solution than unmodified GLP-1 analogs, but cold-chain storage is still required.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy